Publication:
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.

Simple item page
dc.contributor.authorShah, Jatin
dc.contributor.authorShacham, Sharon
dc.contributor.authorKauffman, Michael
dc.contributor.authorDaniele, Patrick
dc.contributor.authorTomaras, Dimitrios
dc.contributor.authorTremblay, Gabriel
dc.contributor.authorCasasnovas, Rene-Olivier
dc.contributor.authorMaerevoet, Marie
dc.contributor.authorZijlstra, Josee
dc.contributor.authorFollows, George
dc.contributor.authorP Vermaat, Joost S
dc.contributor.authorKalakonda, Nagesh
dc.contributor.authorGoy, Andre Henri
dc.contributor.authorChoquet, Sylvain
dc.contributor.authorDen Neste, Eric Van
dc.contributor.authorHill, Brian T
dc.contributor.authorThieblemont, Catherine
dc.contributor.authorCavallo, Federica
dc.contributor.authorla Cruz, Fátima de
dc.contributor.authorKuruvilla, John
dc.contributor.authorHamad, Nada
dc.contributor.authorBouabdallah, Reda
dc.contributor.authorJäger, Ulrich
dc.contributor.authorCaimi, Paolo
dc.contributor.authorGurion, Ronit
dc.contributor.authorWarzocha, Krzysztof
dc.contributor.authorBakhshi, Sameer
dc.contributor.authorSancho, Juan Manuel
dc.contributor.authorSchuster, Michael
dc.contributor.authorEgyed, Miklós
dc.contributor.authorOffner, Fritz
dc.contributor.authorVasilakopoulos, Theodoros P
dc.contributor.authorSamal, Priyanka
dc.contributor.authorNagy, Agnes
dc.contributor.authorKu, Matthew
dc.contributor.authorCanales Albendea, Miguel Ángel
dc.date.accessioned2023-02-09T10:40:51Z
dc.date.available2023-02-09T10:40:51Z
dc.date.issued2021-02-02
dc.description.abstractAim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT) - Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT - Lymphoma (p ≤ 0.05), FACT - General (p 
dc.identifier.doi10.2217/fon-2020-0946
dc.identifier.essn1744-8301
dc.identifier.pmid33528286
dc.identifier.unpaywallURLhttps://doi.org/10.2217/fon-2020-0946
dc.identifier.urihttp://hdl.handle.net/10668/17083
dc.issue.number11
dc.journal.titleFuture oncology (London, England)
dc.journal.titleabbreviationFuture Oncol
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number1295-1310
dc.pubmedtypeClinical Trial, Phase II
dc.pubmedtypeJournal Article
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectEQ-5D-5L
dc.subjectFACT-Lym
dc.subjectdiffuse large B-cell lymphoma
dc.subjectdisutility of adverse events
dc.subjecthealth state utility
dc.subjecthealth utility
dc.subjecthealth-related quality of life
dc.subjectpatient-reported outcomes
dc.subjectselinexor
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshDrug Resistance, Neoplasm
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshHydrazines
dc.subject.meshLymphoma, Large B-Cell, Diffuse
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPatient Reported Outcome Measures
dc.subject.meshQuality of Life
dc.subject.meshRecurrence
dc.subject.meshTriazoles
dc.titleHealth-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number17
dspace.entity.typePublication

Files

Collections

SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía